BioSpace News Archive

GoHealth, Inc. (GoHealth) (NASDAQ: GOCO), announced that the company will release its financial results for the second quarter of fiscal year 2022 on August 15, 2022 after 4:00 p.m. (ET), followed by a conference call/live audio webcast to discuss the results at 5:00 p.m. (ET).

Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that it intends to offer and sell $250 million of American Depositary Shares (“ADSs”), each representing two ordinary shares, in an underwritten public offering.

Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced it has commenced a process to explore and evaluate strategic options to enhance and preserve shareholder value.

Altus Power, Inc. (“Altus Power”) (NYSE: AMPS), the premier independent owner and operator of commercial-scale solar facilities, today announced that it will release financial results for the second quarter of 2022 before the market opens on Monday, August 15, 2022.

Nkarta, Inc., a clinical-stage biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, announced the promotions of Ralph Brandenberger, PhD, to Chief Technical Officer and Yvonne Li, MBA, to Chief Administrative Officer.

Eisai Co. Ltd (Headquarters: Toyoko, CEO: Haruo Naito, “Eisai”) announced today that the company will present research from its Alzheimer’s disease (AD) pipeline, including new data for lecanemab (BAN2401).

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, will release its second-quarter 2022 financial results on Thursday, Aug. 4, 2022.

Nanoscope Therapeutics Inc. today announced that the first patient has been dosed in a Phase 2 trial of its Multi-Characteristic Opsin (MCO-010) ambient-light activatable optogenetic monotherapy for Stargardt disease.

Centene Corporation announced that as part of its previously announced review of strategic alternatives for its international portfolio, it has signed a definitive agreement to sell to Vivalto Santé its Spanish and Central European businesses.

Precision BioSciences, Inc., a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, announced that, on July 19, 2022, the Compensation Committee of Precision’s Board of Directors approved the grant of inducement awards to new employees under the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan.